A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the drugs work, according to a new study led by researchers at the Brown University School of Public Health.
May 18, 2026
0
14
Cognitive decline in Alzheimer's disease differs substantially from one person to the next and is not well predicted by existing medical tests. Among people with preclinical Alzheimer's disease who began one of two related ...
Apr 28, 2026
0
19
In the fight against Alzheimer's, researchers at the Technical University of Munich (TUM) have developed a promising, preventative therapeutic approach. They specifically targeted the amyloid beta biomolecule, which triggers ...
Aug 14, 2024
1
53
Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study, the first and largest clinical trial of pre-symptomatic Alzheimer's disease, is now widely available to researchers studying the condition. The ...
Jul 23, 2024
0
41
A five-year, £5 million initiative has just been launched to investigate the feasibility of using new blood tests in the diagnosis of Alzheimer's disease. Alzheimer's Research UK and the Alzheimer's Society are working with ...
Nov 20, 2023
0
60
For patients with preclinical Alzheimer disease, solanezumab does not slow cognitive decline, according to a study published online July 17 in the New England Journal of Medicine to coincide with the annual Alzheimer's Association ...
Jul 19, 2023
0
54
Preliminary results from a landmark clinical trial to prevent Alzheimer's disease (AD) symptoms show that an investigational anti-amyloid drug, solanezumab, did not demonstrate a statistically significant slowing of cognitive ...
Mar 9, 2023
0
47
